Nu Skin Q3 2026 revenue falls 14.6% to $311M

The 2026 outlook calls for revenue of $1.26 billion to $1.29 billion and adjusted EPS of $0.55 to $0.65.

Available on EDGAR 11/05/2026 - 04:22 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nu Skin Enterprises, Inc. (NUS) reported third-quarter 2026 revenue of $311.0 million, down 14.6% from $364.2 million a year earlier; constant-currency revenue declined 13.5%. Diluted EPS was $(0.02), versus $0.34, while diluted EPS excluding certain charges was $0.10. Net loss was $0.7 million, compared with net income of $17.1 million, and operating margin was 1.6%, versus 5.9%. Customers fell 18% to 609,469; paid affiliates fell 10% to 116,449; and sales leaders fell 13% to 26,995.

For the first nine months, revenue was $951.7 million, down 14.6%, and net loss was $248.7 million, versus net income of $145.7 million. Nine-month results included $80.7 million of impairment expenses, and the tax provision included a $167.5 million impact from a valuation allowance on deferred tax assets. Full-year 2026 outlook is revenue of $1.26 billion to $1.29 billion and EPS of $(5.08) to $(4.98), or adjusted EPS of $0.55 to $0.65. Q4 revenue outlook is $310 million to $340 million, with adjusted EPS of $0.11 to $0.21; management anticipates sequential growth in Q4.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• None.

Negative

• Major pointNine-month net loss was $248.7 million, versus $145.7 million net income.
• Moderate pointQ3 revenue fell 14.6% to $311.0 million.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 revenue outlook reflects a (15)% to (13)% change.

Filing Explained

For the third quarter, Nu Skin reports $2.9 million in dividend payments and no stock repurchases; $137.3 million remained in the repurchase authorization, not reported as buybacks made during the quarter.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q3 revenue: $311.0 million Diluted EPS: $(0.02) per share Diluted EPS excluding certain charges: $0.10 per share +5 more

8 metrics

Q3 revenue $311.0 million Third quarter 2026; down 14.6% from $364.2 million in 2025

Diluted EPS $(0.02) per share Third quarter 2026; compared with $0.34 in 2025

Diluted EPS excluding certain charges $0.10 per share Third quarter 2026; compared with $0.34 in 2025

Operating margin 1.6% Third quarter 2026; compared with 5.9% in 2025

Nine-month revenue $951.7 million Nine months ended September 30, 2026; down 14.6% from $1,114.8 million

Nine-month net loss $(248.7) million Nine months ended September 30, 2026; compared with $145.7 million net income

Full-year revenue outlook $1.26 billion to $1.29 billion 2026 outlook; change of (15)% to (13)%

Adjusted EPS outlook $0.55 to $0.65 per share Full-year 2026 outlook

Key Terms

constant-currency revenue change, adjusted EPS, valuation allowance on deferred tax assets, operating margin

4 terms

constant-currency revenue change financial

"Constant-currency revenue change is a non-GAAP financial measure"

adjusted EPS financial

"Adjusted EPS"

Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.

valuation allowance on deferred tax assets financial

"Impact of valuation allowance on deferred tax assets"

A valuation allowance on deferred tax assets is an accounting reserve a company sets up when it doubts it will be able to use tax benefits it has recorded, such as past losses or tax credits, to reduce future taxes. Think of it like marking down the value of a coupon because you’re unlikely to use it; it matters to investors because increasing the allowance can reduce reported profits and suggest weaker future cash tax savings and lower financial strength.

operating margin financial

"Operating margin, excluding certain charges"

Operating margin shows how much profit a company makes from its core business activities after paying for costs like wages and materials. It’s useful because it tells you how efficiently a company is running—higher margins mean it keeps more money from each dollar of sales, which can indicate better management or stronger products.

Earnings Snapshot

Revenue: $311.0 million · Guidance included

Third quarter 2026

Revenue $311.0 million Down 14.6% year over year

Diluted EPS $(0.02) per share Compared with $0.34

Diluted EPS excluding certain charges $0.10 per share Compared with $0.34

Operating margin 1.6% Compared with 5.9%

Guidance

Q4 2026 revenue: $310 million to $340 million; EPS: $0.05 to $0.15, or adjusted EPS: $0.11 to $0.21. Full-year 2026 revenue: $1.26 billion to $1.29 billion; EPS: $(5.08) to $(4.98), or adjusted EPS: $0.55 to $0.65.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was NUS's revenue in Q3 2026?

NUS reported $311.0 million in third-quarter 2026 revenue, down 14.6% from $364.2 million a year earlier. The reported constant-currency change was (13.5)%.

What were NUS's Q3 2026 earnings per share?

Diluted EPS was $(0.02) per share, compared with $0.34 a year earlier; diluted EPS excluding certain charges was $0.10. Net loss was $0.7 million, compared with net income of $17.1 million.

What is NUS's 2026 financial outlook?

Nu Skin projected full-year 2026 revenue of $1.26 billion to $1.29 billion and EPS of $(5.08) to $(4.98), or adjusted EPS of $0.55 to $0.65. For Q4, it projected revenue of $310 million to $340 million and adjusted EPS of $0.11 to $0.21.

What charges affected NUS's Q3 2026 results?

Third-quarter other charges included $5.1 million in employee severance charges and $1.2 million in professional fees. The company also reported diluted EPS excluding the impact of certain charges of $0.10.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000102156100010215612026-11-052026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	November 5, 2026
	Date of Report (Date of earliest event reported)
	NU SKIN ENTERPRISES, INC.
	(Exact name of registrant as specified in its charter)
Delaware		001-12421		87-0565309
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)
	75 West Center Street Provo, Utah 84601
	(Address of principal executive offices and zip code)
	(801) 345-1000
	(Registrant’s telephone number, including area code)
	N/A
	(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $.001 par value	NUS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and nine-month periods ended September 30, 2026, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Nu Skin Enterprises’ press release dated November 5, 2026, regarding financial results for the three- and nine-month periods ended September 30, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

/s/ Chelsea K. Lantz

Chelsea K. Lantz

Chief Financial Officer

Date: November 5, 2026

Exhibit 99.1

FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Third Quarter Earnings

PROVO, Utah — Nov. 5, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced third quarter revenue within its guidance range.

Executive Summary

Q3 2026 vs. Prior-year Quarter

Revenue	$311.0 million; (14.6)% •          (1.1)% FX impact or $(3.9) million
Earnings Per Share (EPS)	$(0.02) or $0.10 excluding certain charges compared to $0.34
Customers	609,469; (18)%
Paid Affiliates	116,449; (10)%
Sales Leaders	26,995; (13)%

“Third quarter revenue came in within our guidance range as we continued executing on our strategic priorities amid a challenging operating environment,” said Ryan Napierski, Nu Skin president and CEO. “During the quarter, we held our Nu Skin LIVE global convention in Japan, where we were excited to gather with 12,000 of our sales leaders and preview our next anti-aging offerings focused on women’s health. We continue to see adoption of our Prysm iO platform, including year-to-date growth in revenue from our flagship LifePak nutritional supplements. Looking ahead, we are focused on driving affiliate and customer engagement through the holiday season and anticipate sequential growth in the fourth quarter.”

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 2

Q3 2026 Year-over-year Operating Results

Revenue	$311.0 million compared to $364.2 million •          (1.1)% FX impact or $(3.9) million
Gross Margin	65.0% compared to 70.5% •          Nu Skin business was 76.6% compared to 77.7%
Selling Expenses	33.2% compared to 35.8% •          Nu Skin business was 40.9% compared to 41.7%
G&A Expenses	30.2% compared to 28.8%
Operating Margin	1.6% or 3.7% excluding certain charges compared to 5.9%
Interest Expense	$3.5 million compared to $4.1 million
Other Income/ (Expense)	$0.3 million compared to $(1.5) million
Income Tax Rate	139.3% or 42.7% excluding certain charges compared to (6.8)%
EPS	$(0.02) or $0.10 excluding certain charges compared to $0.34

Stockholder Value

Dividend Payments	$2.9 million
Stock Repurchases	$0.0 million •          $137.3 million remaining in authorization

Q4 and Full-year 2026 Outlook

Q4 2026 Revenue	$310 to $340 million; (16)% to (8)% •          Approximately 1% FX impact
Q4 2026 EPS	$0.05 to $0.15 or $0.11 to $0.21 on an adjusted basis
2026 Revenue	$1.26 to $1.29 billion; (15)% to (13)% •          Approximately (1)% FX impact
2026 EPS	$(5.08) to $(4.98) or $0.55 to $0.65 on an adjusted basis

“For 2026, we project revenue of $1.26 billion to $1.29 billion and earnings per share of $(5.08) to $(4.98) with adjusted EPS of $0.55 to $0.65,” said Chelsea Lantz, interim chief financial officer. “For the fourth quarter, we project revenue between $310 million and $340 million, with earnings per share in the range of $0.05 to $0.15 or $0.11 to $0.21 on an adjusted basis.”

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 3

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Nov. 19, 2026.

About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty and wellness device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 4

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, and affiliates and customers; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” "focus," “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve important risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

• risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

• economic conditions and events globally;

• the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;

• competitive pressures in the company’s markets;

• risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;

• adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

• political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

• risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

• uncertainties regarding the future financial performance of the businesses the company has acquired;

• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and

• regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 5

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin, and income tax rate, each excluding severance charges, cash-based transition costs, and/or other charges, also are non-GAAP financial measures.

• Severance charges and cash-based transition costs are not part of the ongoing operations of our underlying business; and

• The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing operations.

The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 6

The following table sets forth revenue for the three-month periods ended September 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

		Three Months Ended												Constant-
		September 30,												Currency
		2026				2025				Change				Change
Nu Skin
Americas		$	53,092			$	63,994				(17.0	)%			(15.9	)%
Southeast Asia/Pacific			43,032				56,285				(23.5	)%			(23.2	)%
Mainland China			37,888				42,519				(10.9	)%			(16.1	)%
Japan			38,627				44,545				(13.3	)%			(6.5	)%
Europe & Africa			27,898				38,002				(26.6	)%			(25.4	)%
Hong Kong/Taiwan			25,739				31,799				(19.1	)%			(15.2	)%
South Korea			24,410				35,202				(30.7	)%			(29.3	)%
Nu Skin Other			1,888				244				673.8	%			673.8	%
Total Nu Skin			252,574				312,590				(19.2	)%			(18.0	)%
Rhyz
Manufacturing			56,831				47,648				19.3	%			19.3	%
Rhyz Other			1,604				3,973				(59.6	)%			(59.6	)%
Total Rhyz			58,435				51,621				13.2	%			13.2	%
Total		$	311,009			$	364,211				(14.6	)%			(13.5	)%

The following table sets forth revenue for the nine-month periods ended September 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

		Nine Months Ended												Constant-
		September 30,												Currency
		2026				2025				Change				Change
Nu Skin
Americas		$	170,673			$	205,998				(17.1	)%			(14.8	)%
Southeast Asia/Pacific			131,763				159,291				(17.3	)%			(18.8	)%
Mainland China			128,992				143,518				(10.1	)%			(15.0	)%
Japan			116,509				131,860				(11.6	)%			(5.5	)%
Europe & Africa			91,433				108,351				(15.6	)%			(18.7	)%
Hong Kong/Taiwan			79,270				87,773				(9.7	)%			(8.5	)%
South Korea			75,359				101,785				(26.0	)%			(23.3	)%
Nu Skin Other			1,733				1,200				44.4	%			44.3	%
Total Nu Skin			795,732				939,776				(15.3	)%			(14.9	)%
Rhyz
Manufacturing			148,125				163,338				(9.3	)%			(9.3	)%
Rhyz Other			7,872				11,725				(32.9	)%			(32.9	)%
Total Rhyz			155,997				175,063				(10.9	)%			(10.9	)%
Total		$	951,729			$	1,114,839				(14.6	)%			(14.3	)%

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 7

The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended September 30, 2026 and 2025.

		Three Months Ended
		September 30,
		2026				2025				Change
Customers
Americas			162,865				224,013				(27	)%
Southeast Asia/Pacific			66,791				74,672				(11	)%
Mainland China			90,469				106,062				(15	)%
Japan			99,256				107,543				(8	)%
Europe & Africa			100,615				127,993				(21	)%
Hong Kong/Taiwan			36,903				41,613				(11	)%
South Korea			52,570				64,360				(18	)%
Total Customers			609,469				746,256				(18	)%
Paid Affiliates
Americas			26,023				28,128				(7	)%
Southeast Asia/Pacific			17,587				21,144				(17	)%
Mainland China			17,121				18,197				(6	)%
Japan			19,278				20,559				(6	)%
Europe & Africa			12,646				14,803				(15	)%
Hong Kong/Taiwan			9,370				10,154				(8	)%
South Korea			14,424				17,111				(16	)%
Total Paid Affiliates			116,449				130,096				(10	)%
Sales Leaders
Americas			4,635				5,642				(18	)%
Southeast Asia/Pacific			3,900				4,360				(11	)%
Mainland China			5,889				6,543				(10	)%
Japan			6,154				6,686				(8	)%
Europe & Africa			2,111				2,663				(21	)%
Hong Kong/Taiwan			1,956				2,174				(10	)%
South Korea			2,350				3,082				(24	)%
Total Sales Leaders			26,995				31,150				(13	)%

• “Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

• “Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

• “Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 8

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Revenue		$	311,009			$	364,211			$	951,729			$	1,114,839
Cost of sales			108,842				107,488				316,774				345,422
Gross profit			202,167				256,723				634,955				769,417
Operating expenses:
Selling expenses			103,207				130,264				321,183				377,038
General and administrative expenses			93,873				104,817				283,264				324,746
Impairment expenses			-				-				80,714				25,114
Total operating expenses			197,080				235,081				685,161				726,898
Operating income (loss)			5,087				21,642				(50,206	)			42,519
Interest expense			3,499				4,145				11,071				9,954
Gain on sale of business			-				-				-				176,162
Other income (expense), net			299				(1,503	)			2,588				(30,721	)
Income (loss) before provision for income taxes			1,887				15,994				(58,689	)			178,006
Provision (benefit) for income taxes			2,629				(1,085	)			190,015				32,293
Net income (loss)		$	(742	)		$	17,079			$	(248,704	)		$	145,713
Net income (loss) per share:
Basic		$	(0.02	)		$	0.35			$	(5.13	)		$	2.94
Diluted		$	(0.02	)		$	0.34			$	(5.13	)		$	2.91
Weighted-average common shares outstanding (000s):
Basic			48,677				49,398				48,495				49,533
Diluted			48,677				50,310				48,495				50,158

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 9

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

		September 30,				December 31,
		2026				2025
ASSETS
Current assets:
Cash and cash equivalents		$	164,903			$	238,630
Current investments			1,736				1,211
Accounts receivable, net			51,406				39,544
Inventories, net			191,656				178,643
Prepaid expenses and other			69,716				89,670
Total current assets			479,417				547,698
Property and equipment, net			382,935				377,168
Operating lease right-of-use assets			63,667				74,021
Goodwill			4,750				83,625
Other intangible assets, net			36,384				42,614
Other assets			120,925				280,187
Total assets			1,088,078				1,405,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	26,235			$	26,183
Accrued expenses			188,950				217,551
Current portion of long-term debt			20,000				20,000
Total current liabilities			235,185				263,734
Operating lease liabilities			48,683				57,640
Long-term debt			183,734				204,187
Other liabilities			72,994				74,512
Total liabilities			540,596				600,073
Commitments and contingencies
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued			91				91
Additional paid-in capital			615,121				635,994
Treasury stock, at cost – 41.9 million and 42.4 million shares			(1,558,183	)			(1,575,059	)
Accumulated other comprehensive loss			(112,447	)			(116,105	)
Retained earnings			1,602,900				1,860,319
Total stockholders' equity			547,482				805,240
Total liabilities and stockholders’ equity		$	1,088,078			$	1,405,313

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 10

NU SKIN ENTERPRISES, INC. Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin (in thousands)

		Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
Operating Income		$	5,087			$	21,642			$	(50,206	)		$	42,519
Impact of inventory write-off			-				-				3,116				-
Impact of other charges(1)			6,314				-				8,957				7,966
Impact of impairment expenses			-				-				80,714				25,114
Adjusted operating income		$	11,401			$	21,642			$	42,581			$	75,599
Operating margin			1.6	%			5.9	%			(5.3	)%			3.8	%
Operating margin, excluding certain charges			3.7	%			5.9	%			4.5	%			6.8	%
Revenue		$	311,009			$	364,211			$	951,729			$	1,114,839

(1) Other charges for the third quarter of 2026 consist of $5.1 million related to employee severance charges and $1.2 million of  professional fees. Other charges for the first nine months of 2026 consist of the aforementioned $6.3 million as well as $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first nine months of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 11

NU SKIN ENTERPRISES, INC. Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate (in thousands)

		Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
Provision (benefit) for income taxes		$	2,629			$	(1,085	)		$	190,015			$	32,293
Impact of inventory write-off on provision for income taxes			-				-				1,065				-
Impact of other charges on provision for income taxes(1)			873				-				1,776				725
Impact of impairment on provision for income taxes			-				-				(12,741	)			5,433
Impact of gain on Mavely sale on provision for income taxes			-				-				-				(31,104	)
Impact of gain on unrealized investment loss on provision for income taxes			-				-				-				6,074
Impact of valuation allowance on deferred tax assets			-				-				(167,505	)			-
Provision for income taxes, excluding impact of certain charges		$	3,502			$	(1,085	)		$	12,610			$	13,421
Income before provision for income taxes			1,887				15,994				(58,689	)			178,006
Impact of inventory write-off			-				-				3,116				-
Impact of other charges(1)			6,314				-				8,957				7,966
Impact of impairment expense:			-				-				80,714				25,114
Impact of gain on Mavely sale			-				-				-				(176,162	)
Impact of unrealized investment loss			-				-				-				28,077
Income before provision for income taxes, excluding impact certain charges		$	8,201			$	15,994			$	34,098			$	63,001
Effective tax rate			139.3	%			(6.8	)%			(323.8	)%			18.1	%
Effective tax rate, excluding impact of certain charges			42.7	%			(6.8	)%			37.0	%			21.3	%

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 12

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

(in thousands, except for per share amounts)

		Three months ended September 30,								Nine months ended September 30,
		2026				2025				2026				2025
Net income		$	(742	)		$	17,079			$	(248,704	)		$	145,713
Impact of Inventory write-off
Inventory write-off			-				-				3,116				-
Tax impact			-				-				(1,065	)			-
Impact of other charges
Other charges(1)			6,314				-				8,957				7,966
Tax impact			(873	)			-				(1,776	)			(725	)
Impact of impairment
Impairment charges			-				-				80,714				25,114
Tax impact			-				-				12,741				(5,433	)
Impact of Mavely sale
Mavely sale			-				-				-				(176,162	)
Tax impact			-				-				-				31,104
Impact of unrealized investment loss
Unrealized investment loss			-				-				-				28,077
Tax impact			-				-				-				(6,074	)
Impact of valuation allowance on deferred tax assets			-				-				167,505				-
Adjusted net income		$	4,699			$	17,079			$	21,488			$	49,580
Diluted earnings per share		$	(0.02	)		$	0.34			$	(5.13	)		$	2.91
Diluted earnings per share, excluding impact of certain charges		$	0.10			$	0.34			$	0.44			$	0.99
Weighted-average common shares outstanding (000)			48,677				50,310				48,495				50,158

Nu Skin Enterprises Reports Third Quarter 2026 Financial Results  page 13

NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

		Three months ended December 31, 2026								Year ended December 31, 2026
		Low end				High end				Low end				High end
Earnings Per Share		$	0.05			$	0.15			$	(5.08	)		$	(4.98	)
Impact of inventory write-off
Inventory write-off			-				-				0.06				0.06
Tax impact			-				-				(0.02	)			(0.02	)
Impact of other charges
Other charges(2)			0.10				0.10				0.29				0.29
Tax impact			(0.04	)			(0.04	)			(0.08	)			(0.08	)
Impact of impairment:
Impairment charges			-				-				1.67				1.67
Tax impact			-				-				0.26				0.26
Impact of valuation allowance on deferred tax assets			-				-				3.45				3.45
Adjusted EPS		$	0.11			$	0.21			$	0.55			$	0.65

(2) We are currently anticipating other charges for the fourth quarter of 2026 of approximately $5.0 million in cash-based transition cost. Other charges for the first nine months of 2026 consist of $6.7 million related to employee severance charges, $1.2 million of professional fees and as well as $1.0 million related to the wind down of the separate BeautyBio business.

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397

Investors: investorrelations@nuskin.com, (801) 345-3577

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 PRESS RELEASE DATED NOVEMBER 5, 2026 612.1 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB